New drug HMB-001 aims to curb dangerous bleeds in rare blood disorder
NCT ID NCT06211634
First seen Jan 02, 2026 · Last updated May 13, 2026 · Updated 27 times
Summary
This early-stage trial tests a new medicine called HMB-001 in about 57 people with Glanzmann thrombasthenia, a rare bleeding disorder. The study aims to see if the drug is safe and can reduce how often and how severely bleeds occur. Participants receive single or multiple doses over several months, with close monitoring for side effects and bleeding episodes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLANZMANN THROMBASTHENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HM - Hopital de la Timone
Marseille, France
-
AP-HP Hopital Bicetre (Part B/C)
Le Kremlin-Bicêtre, France
-
AP-HP Hopital Necker-Enfants Malades (Part B/C)
Paris, France
-
Azienda Ospedaliero-Universitaria Careggi (Part B/C)
Florence, Italy
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano (Part B/C)
Milan, Italy
-
Hemophilia Center of Western Pennsylvania (HCWP) (Part B/C)
Pittsburgh, Pennsylvania, 15213, United States
-
Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom
-
Mayo Clinic - Rochester (Part B/C)
Rochester, Minnesota, 55905, United States
-
Queen Elizabeth Hospital Birmingham (Part B/C)
Birmingham, United Kingdom
-
Richmond Pharmacology Ltd (Part A/B/C)
London, United Kingdom
-
Royal Free London NHS Foundation Trust (Part B/C)
London, United Kingdom
-
The Royal London Hospital (Part B/C)
Whitechapel, United Kingdom
-
Tulane University Medical Center (Part B/C)
New Orleans, Louisiana, 70112, United States
-
Universitair Medisch Centrum Utrecht (Part B/C)
Utrecht, Netherlands
-
University Hospital Leuven - Campus Gasthuisberg (Part B/C)
Leuven, Belgium
-
University of California, San Diego (UCSD) (Part B/C)
La Jolla, California, 92093, United States
-
Washington Institute for Coagulation (Part B/C)
Seattle, Washington, 98101, United States
Conditions
Explore the condition pages connected to this study.